The Impact of COVID-19 Vaccination on Symptoms of Anxiety and Depression before and after COVID-19 Vaccines Were Universally Available for Adults in the United States

Table 2

Impact of COVID-19 vaccination on moderate to severe symptoms of anxiety and depression prior to and during universal availability of the COVID-19 vaccine—CHASING COVID Cohort, USA, December 2020-January 2022.

Vaccination status and vaccine era	Person-trial denominator	Moderate or severe symptoms of anxiety				Moderate or severe symptoms of depression
			Prevalence (95% CI)	OR (95% CI)	aOR (95% CI)		Prevalence (95% CI)	OR (95% CI)	aOR (95% CI)
Preuniversal availability
Not vaccinated	4846	1171	24.2 (23.0, 25.4)	1.00	1.00	1231	25.4 (24.2, 26.6)	1.00	1.00
Vaccinated	3194	532	16.7 (15.4, 17.9)	0.70 (0.65, 0.76)	0.79 (0.70, 0.89)	653	20.4 (19.0, 21.8)	0.82 (0.77, 0.88)	0.92 (0.82, 1.03)
Universal availability
Not vaccinated	2628	706	26.9 (25.2, 28.6)	1.00	1.00	782	29.8 (28.0, 31.5)	1.00	1.00
Vaccinated	801	219	27.3 (24.3, 30.4)	1.06 (0.92, 1.22)	1.23 (1.00, 1.50)	234	29.2 (26.1, 32.4)	1.03 (0.89, 1.18)	1.11 (0.91, 1.36)

Adjusted for baseline access to healthcare, baseline age, anxiety at time 0, baseline education, employment at time 0, gender, housing and food insecurity at time 0, and baseline susceptibility to severe COVID-19. Std errors adjusted for repeat subjects. Adjusted for baseline access to healthcare, baseline age, depression at time 0, baseline education, employment at time 0, gender, housing and food insecurity at time 0, and baseline susceptibility to severe COVID-19. Std errors adjusted for repeat subjects.